Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Second-Generation Antidepressants for Treating Adult Depression—An Update

Slide: 21 of 28

Specific Comparative Harms of Second-Generation Antidepressants for Adults With MDD (1 of 3)

There is high-strength evidence that venlafaxine has a 52-percent higher incidence of nausea and vomiting than selective serotonin reuptake inhibitors as a class. Low-strength evidence suggests that when used to treat major depressive disorder (MDD), paroxetine IR (immediate release) may lead to higher rates of nausea than paroxetine CR (controlled release). The strength of evidence was high that mirtazapine is associated with more weight gain than citalopram, fluoxetine, paroxetine, and sertraline (0.8–3.0 kg after 6–8 weeks). Sertraline was associated with an 8-percent higher incidence of diarrhea than bupropion, citalopram, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, and venlafaxine at a moderate strength of evidence.